Legacy Wealth Management LLC MS Acquires New Stake in IDEXX Laboratories, Inc. $IDXX

Legacy Wealth Management LLC MS acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 916 shares of the company’s stock, valued at approximately $478,000.

Other institutional investors also recently modified their holdings of the company. J.Safra Asset Management Corp bought a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $25,000. Elevation Wealth Partners LLC increased its holdings in IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after purchasing an additional 32 shares in the last quarter. Pension & Wealth Management Advisors Inc. bought a new position in IDEXX Laboratories in the 3rd quarter valued at $29,000. Arlington Trust Co LLC raised its position in IDEXX Laboratories by 46.3% in the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after purchasing an additional 19 shares during the last quarter. Finally, Bell Investment Advisors Inc raised its position in IDEXX Laboratories by 45.5% in the 3rd quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock valued at $33,000 after purchasing an additional 20 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Trending Headlines about IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates. IDEXX reported adjusted earnings of approximately $3.96–$3.98 per share versus the $3.71 consensus estimate. Revenue rose about 10% year over year to $1.21 billion, exceeding expectations of roughly $1.19 billion. IDEXX Laboratories Q3 earnings report
• Positive Sentiment: Recurring diagnostics remained the key growth engine. Recurring diagnostic revenue to veterinarians increased about 11%, demonstrating continued demand for IDEXX’s testing platforms and supporting the company’s earnings growth despite softer veterinary visit trends. IDEXX raises forecast
• Positive Sentiment: Management raised its full-year 2026 earnings and revenue guidance. The revised outlook suggests that IDEXX expects diagnostics growth, operating performance and customer adoption of its offerings to offset weakness in veterinary visit volumes. The guidance increase was the primary catalyst behind the strong stock reaction. IDEXX revises 2026 earnings guidance
• Neutral Sentiment: The earnings call reinforced a favorable long-term growth narrative. Management highlighted continued expansion in diagnostics, recurring revenue and productivity initiatives, which may support durable growth but also leaves the stock reliant on sustained premium valuation expectations. IDEXX Laboratories earnings call highlights
• Negative Sentiment: Margin trends and veterinary demand remain risks. Some reports noted that the higher profit forecast was not driven by stronger testing demand, while the margin outlook softened. Weak veterinary visits could pressure near-term volume growth if diagnostics expansion does not continue. IDEXX sales and margin outlook

Analyst Upgrades and Downgrades

A number of research firms have commented on IDXX. Citigroup boosted their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. KeyCorp initiated coverage on IDEXX Laboratories in a research note on Monday, October 12th. They issued a “sector weight” rating for the company. JPMorgan Chase & Co. cut their price target on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a report on Friday, October 16th. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Finally, Jefferies Financial Group reduced their price target on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a research report on Tuesday, October 20th. Eight analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $721.67.

Insider Activity at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.79% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $671.64 on Tuesday. IDEXX Laboratories, Inc. has a one year low of $500.61 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The company’s 50 day simple moving average is $536.56 and its 200-day simple moving average is $573.88. The stock has a market capitalization of $52.91 billion, a P/E ratio of 47.23 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same quarter last year, the business posted $3.22 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 9.9% compared to the same quarter last year. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.